ArticleQuantitative imaging in medicine and surgery2025
Exploring the risk factors for the growth of pure ground-glass nodules in a 3-year follow-up period.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Advances in the Growth Risk Assessment and Precision Management of Pulmonary Subsolid Nodules].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pure ground-glass nodules (pGGNs) present management challenges due to their unpredictable growth patterns. This study aimed to assess the clinical and radiological factors associated with the growth of pGGNs within a 3-year follow-up period, and to provide a basis for individualized clinical management strategies. Methods: A retrospective analysis of 93 patients with 138 pGGNs who underwent computed tomography (CT) follow-up examinations for more than 3 years was conducted. The patients were divided into the growth and stable groups, and the relationship between their clinical data and CT findings, and the growth of the pGGNs in the 3-year follow-up period was analyzed. Results: Of the 138 pGGNs, 25 showed growth and 113 remained stable over the 3-year follow-up period. In the patient-based analysis, the frequency of pGGN growth within 3 years was 23.7% (22/93). In the nodule-based analysis, the growth frequency was 18.1% (25/138). In the multivariate analysis, an initial diameter ≥8.5 mm [odds ratio (OR): 78.367, 95% confidence interval (CI): 14.431-425.557, P<0.001] and an irregular pGGN shape (OR: 12.719, 95% CI: 1.731-93.449, P=0.012) were identified as independent risk factors for growth within 3 years. Conclusions: When pGGNs have a maximum diameter ≥8.5 mm and an irregular shape, active surgical intervention may be a more appropriate clinical management approach than continued follow-up observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.